Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-Label Exemestane Adjuvant Safety Surveillance Program: Adjuvant Exemestane (Aromasin) Treatment Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer (IES Inclusion Criteria)

NCT00649090 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00649090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00649090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-Label Exemestane Adjuvant Safety Surveillance Program: Adjuvant Exemestane (Aromasin) Treatment Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer (IES Inclusion Criteria)
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2005
Completion date
April 30, 2007
Enrollment
1,549 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms